Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations | Zendy

Jill Butterfield | Zendy; Thomas P. Lodise | Zendy; Scott Beegle | Zendy; Jonathan M. Rosen | Zendy; Joshua D. Farkas | Zendy; Manjunath P. Pai | Zendy

Open Access

Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations

Author(s) -

Jill Butterfield,

Thomas P. Lodise,

Scott Beegle,

Jonathan M. Rosen,

Joshua D. Farkas,

Manjunath P. Pai

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt300

Subject(s) - piperacillin/tazobactam , piperacillin , medicine , tazobactam , pharmacodynamics , cystic fibrosis , dosing , pharmacokinetics , population , anesthesia , pharmacology , intensive care medicine , pseudomonas aeruginosa , biology , genetics , bacteria , environmental health

Given the high frequency of acute pulmonary exacerbations due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF), piperacillin/tazobactam is commonly used in empirical regimens. While extended-infusion piperacillin/tazobactam has been employed as one strategy to optimize this agent's pharmacodynamics, this approach has not been well characterized in patients with CF. The objectives of this study were to characterize the pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with CF and derive optimized piperacillin/tazobactam dosing recommendations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research